Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Zemplar (1S,3S)-5-[(2E)-2- [(1R,3aR,7aR)-1-[(E,2S...

Synonyms: Paracalcin, Paricalcitol, Compound-49510, PubChem18825, Zemplar (TN), ...

Takahashi, F. et al., Finch, J.L. et al., Slatopolsky, E. et al., Slatopolsky, E. et al., Jokihaara, J. et al.

Slatopolsky, Finch, Brown,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Paricalcitol

Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease [1].
With its ability to suppress PTH at noncalcemic doses, 19-nor-1,25-(OH)2D2 is a potential therapeutic tool for the treatment of secondary hyperparathyroidism in chronic renal failure [2].
A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia [3].

High impact information on Paricalcitol

Parathyroidectomized rats received daily intraperitoneal injections of vehicle, 1,25-(OH)2D3 (100 ng), or 19-nor-1,25-(OH)2D2 (100 or 1000 ng) for 9 d [2].
In the current study, we examined the effect of 19-nor-1,25-(OH)2D2 on parathyroid gland growth and intestinal vitamin D receptor (VDR) content [4].
Currently, two analogs, 19-nor-1,25-(OH)2D2 and 1,alpha(OH)D2, are being used for the treatment of secondary hyperparathyroidism in the United States, and two are being used in Japan, 22-oxa-calcitriol and 1,25-(OH)2-26,27F6 D3 [5].

Anatomical context of Paricalcitol

Thus, 19-nor-1,25-(OH)2D2 appears to exert a selective action on the parathyroid glands compared with the intestine [4].

Gene context of Paricalcitol

The 100-ng dose of 19-nor-1,25-(OH)2D2 decreased PTH to 20.7 +/- 3.1 pg/mL (P < 0.01) and suppressed parathyroid gland growth by more than 50% [4].

References

Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. Jokihaara, J., Pörsti, I., Pajamäki, I., Vuohelainen, T., Jolma, P., Kööbi, P., Kalliovalkama, J., Niemelä, O., Kannus, P., Sievänen, H., Järvinen, T.L. J. Bone Miner. Res. (2006) [Pubmed]
Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. Finch, J.L., Brown, A.J., Slatopolsky, E. J. Am. Soc. Nephrol. (1999) [Pubmed]
A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Slatopolsky, E., Finch, J., Ritter, C., Denda, M., Morrissey, J., Brown, A., DeLuca, H. Am. J. Kidney Dis. (1995) [Pubmed]
A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Takahashi, F., Finch, J.L., Denda, M., Dusso, A.S., Brown, A.J., Slatopolsky, E. Am. J. Kidney Dis. (1997) [Pubmed]
New vitamin D analogs. Slatopolsky, E., Finch, J., Brown, A. Kidney Int. Suppl. (2003) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg